Evaluating Outcomes and Misuse in Opioid-Dependent Chronic Pancreatitis Using a State-Mandated Monitoring System.


Journal

Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782

Informations de publication

Date de publication:
12 2022
Historique:
received: 10 10 2021
accepted: 18 02 2022
pubmed: 20 3 2022
medline: 16 11 2022
entrez: 19 3 2022
Statut: ppublish

Résumé

Patients with chronic pancreatitis (CP) often require opioids for pain control. The goal of our study was to characterize opioid use in patients with CP in a real-life practice using a state-mandated online monitoring program and to assess outcomes compared to CP patients without opioid dependency. CP patients seen in our Pancreas Center from 2016 to 2021 were divided into two groups-with and without chronic opioid use. Details of opioids and other controlled prescriptions were obtained by review of the Massachusetts Prescription Awareness Tool (MassPat). Of the 442 CP outpatients, 216 used chronic opioids. Patients with opioid use had significantly more recurrent acute pancreatitis (76.6% vs. 52.7%), concurrent alcohol use (11.2% vs. 5.8%), tobacco use (37.8% vs. 19.7%), anxiety (22.4% vs. 16.6%), depression (43.5% vs. 23.5%) and daily pain (59.8% vs. 24.8%) (p < 0.001). They also concurrently used more benzodiazepines (43.7% vs. 12.4%), gabapentinoids (66.4% vs. 31.1%) and medical marijuana (14.9% vs. 4.19%) (p < 0.001). They had more celiac plexus blocks (22.0% vs. 6.67%), surgery (18.3% vs. 8.89%) and more hospitalizations for CP flares (3.6 vs. 1.0 visits) (p < 0.001). Less than 13% patients received opioids by means of ED visits; 81.7% patients received their prescriptions from one facility and 75% received them at regular intervals. Opioid-dependent CP patients exhibit polypharmacy and have worse outcomes with higher resource utilization. The state-monitoring program ensures that the majority of patients receive opioids from a single facility, thereby minimizing misuse.

Identifiants

pubmed: 35305166
doi: 10.1007/s10620-022-07459-y
pii: 10.1007/s10620-022-07459-y
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5493-5499

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Beyer G, Habtezion A, Werner J, Lerch MM, Mayerle J. Chronic pancreatitis. Lancet 2020;396:499–512.
doi: 10.1016/S0140-6736(20)31318-0 pubmed: 32798493
Singh VK, Drewes AM. Medical management of pain in chronic pancreatitis. Dig Dis Sci 2017;62:1721–1728.
doi: 10.1007/s10620-017-4605-z pubmed: 28523574
Shah I, Sheth SG, Kothari DJ. Pain management in chronic pancreatitis incorporating safe opioid practices: Challenge accepted. World J Gastroenterol 2021;27:3142–3147.
doi: 10.3748/wjg.v27.i23.3142 pubmed: 34163102 pmcid: 8218357
Drewes AM, Bouwense SAW, Campbell CM et al. Guidelines for the understanding and management of pain in chronic pancreatitis. Pancreatology 2017;17:720–731.
doi: 10.1016/j.pan.2017.07.006 pubmed: 28734722
Löhr JM, Dominguez-Munoz E, Rosendahl J et al. United European gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United Eur Gastroenterol J 2017;5:153–199.
doi: 10.1177/2050640616684695
Anderson MA, Akshintala V, Albers KM et al. Mechanism, assessment and management of pain in chronic pancreatitis: Recommendations of a multidisciplinary study group. Pancreatology 2016;16:83–94.
doi: 10.1016/j.pan.2015.10.015 pubmed: 26620965
Olesen SS, Juel J, Graversen C, Kolesnikov Y, Wilder-Smith OH, Drewes AM. Pharmacological pain management in chronic pancreatitis. World J Gastroenterol 2013;19:7292–7301.
doi: 10.3748/wjg.v19.i42.7292 pubmed: 24259960 pmcid: 3831211
Nusrat S, Yadav D, Bielefeldt K. Pain and opioid use in chronic pancreatitis. Pancreas 2012;41:264–270.
doi: 10.1097/MPA.0b013e318224056f pubmed: 21792080
Bilal M, Chatila A, Siddiqui MT et al. Rising prevalence of opioid use disorder and predictors for opioid use disorder among hospitalized patients with chronic pancreatitis. Pancreas 2019;48:1386–1392.
doi: 10.1097/MPA.0000000000001430 pubmed: 31688606
Gostin LO, Hodge JG Jr, Noe SA. Reframing the opioid epidemic as a national emergency. Jama 2017;318:1539–1540.
doi: 10.1001/jama.2017.13358 pubmed: 28832871
Ferris LM, Saloner B, Krawczyk N et al. Predicting opioid overdose deaths using prescription drug monitoring program data. Am J Prev Med 2019;57:e211–e217.
doi: 10.1016/j.amepre.2019.07.026 pubmed: 31753274 pmcid: 7996003
Katz N, Panas L, Kim M et al. Usefulness of prescription monitoring programs for surveillance—analysis of schedule II opioid prescription data in Massachusetts, 1996–2006. Pharmacoepidemiol Drug Saf 2010;19:115–123.
doi: 10.1002/pds.1878 pubmed: 20014166
Adejumo AC, Akanbi O, Alayo Q et al. Predictors, rates, and trends of opioid use disorder among patients hospitalized with chronic pancreatitis. Ann Gastroenterol 2021;34:262–272.
pubmed: 33654369 pmcid: 7903576
Catalano MF, Sahai A, Levy M et al. EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc 2009;69:1251–1261.
doi: 10.1016/j.gie.2008.07.043 pubmed: 19243769
Ahmed A, Yakah W, Freedman SD, Kothari DJ, Sheth SG. Evaluation of opioid use in acute pancreatitis in absence of chronic pancreatitis: Absence of opioid dependence an important feature. Am J Med 2020;133:1209–1218.
doi: 10.1016/j.amjmed.2020.03.010 pubmed: 32272099
Wickham H. The tidyverse. R package ver 2017;1:836.
Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med 2009;10:654–662.
doi: 10.1111/j.1526-4637.2009.00583.x pubmed: 19302436
Keefer L, Drossman DA, Guthrie E, et al. Centrally mediated disorders of gastrointestinal pain. Gastroenterology 2016.
Wang D. Opioid medications in the management of chronic abdominal pain. Curr Pain Headache Rep 2017;21:40.
doi: 10.1007/s11916-017-0640-x pubmed: 28791598
Demir IE, Tieftrunk E, Maak M, Friess H, Ceyhan GO. Pain mechanisms in chronic pancreatitis: Of a master and his fire. Langenbecks Arch Surg 2011;396:151–160.
doi: 10.1007/s00423-010-0731-1 pubmed: 21153480
Alkhayyat M, Abou Saleh M, Coronado W et al. Increasing prevalence of anxiety and depression disorders after diagnosis of chronic pancreatitis: A 5-year population-based study. Pancreas 2021;50:153–159.
doi: 10.1097/MPA.0000000000001746 pubmed: 33565791
Phillips AE, Faghih M, Drewes AM et al. Psychiatric comorbidity in patients with chronic pancreatitis associates with pain and reduced quality of life. Am J Gastroenterol 2020;115:2077–2085.
doi: 10.14309/ajg.0000000000000782 pubmed: 32740078
Scherrer JF, Salas J, Copeland LA et al. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. Ann Fam Med 2016;14:54–62.
doi: 10.1370/afm.1885 pubmed: 26755784 pmcid: 4709156
Boon M, van Dorp E, Broens S, Overdyk F. Combining opioids and benzodiazepines: Effects on mortality and severe adverse respiratory events. Ann Palliat Med 2020;9:542–557.
doi: 10.21037/apm.2019.12.09 pubmed: 32036672
Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med 2013;125:115–130.
doi: 10.3810/pgm.2013.07.2684 pubmed: 23933900 pmcid: 4057040
Alexakis N, Connor S, Ghaneh P et al. Influence of opioid use on surgical and long-term outcome after resection for chronic pancreatitis. Surgery 2004;136:600–608.
doi: 10.1016/j.surg.2004.02.011 pubmed: 15349108
Negi S, Singh A, Chaudhary A. Pain relief after Frey’s procedure for chronic pancreatitis. Br J Surg 2010;97:1087–1095.
doi: 10.1002/bjs.7042 pubmed: 20632276
Ahmed Ali U, Nieuwenhuijs VB, van Eijck CH et al. Clinical outcome in relation to timing of surgery in chronic pancreatitis: A nomogram to predict pain relief. Arch Surg 2012;147:925–932.
pubmed: 23117832
Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 1995;274:1870–1873.
doi: 10.1001/jama.1995.03530230056031 pubmed: 7500538
Whitcomb DC, Shimosegawa T, Chari ST et al. International consensus statements on early chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with The International Association of Pancreatology, American Pancreatic Association, Japan Pancreas Society, PancreasFest Working Group and European Pancreatic Club. Pancreatology 2018;18:516–527.
doi: 10.1016/j.pan.2018.05.008 pubmed: 29793839
Drewes AM, Olesen AE, Farmer AD et al. Gastrointestinal pain. Nat Rev Dis Primers 2020;6:1.
doi: 10.1038/s41572-019-0135-7 pubmed: 31907359

Auteurs

Ishani Shah (I)

Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Rachel Bocchino (R)

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

William Yakah (W)

Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Awais Ahmed (A)

Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Steven D Freedman (SD)

Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Darshan J Kothari (DJ)

Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.

Sunil G Sheth (SG)

Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ssheth@bidmc.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH